Overview: p2PSA TestIntroduction: The p2PSA Test measures p2PSA to assess prostate cancer risk, helping diagnose or monitor conditions causing prostate issues or urinary symptoms. Affecting 1 in 8 men over 60, prostate cancer poses diagnostic challenges due to slow progression. Following 2023 American Urological Association (AUA) guidelines, it uses immunoassay for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, treatment planning, and improving outcomes in urology.
Other Names: p2PSA Level Test, Prostate Cancer Risk Assay.
FDA Status: FDA-approved test, meeting biochemistry standards for diagnostic reliability.
Historical Milestone: p2PSA testing began in the 2000s with research by Catalona, who linked it to cancer. Immunoassay advancements by Beckman Coulter improved detection, surpassing earlier PSA methods.
Purpose: Measures p2PSA levels to assess prostate cancer risk, guides biopsy or monitoring, and evaluates patients with prostate issues, aiming to manage disease.
Test Parameters: p2PSA levels
Pretest Condition: No special preparation required. Collect serum or plasma. Report history of prostate issues.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document prostate issues or urinary symptoms. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, cancer risks, and sample collection risks.
Procedural Considerations: Uses immunoassay to measure p2PSA, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest prostate cancer risk, guiding therapy. Early detection might improve survival, while untreated cases lead to progression. Normal levels may require monitoring.
Specialist Consultation: Consult a urologist for interpretation.
Additional Supporting Tests: PSA test, biopsy, or MRI to confirm diagnosis.
Test Limitations: Non-specific for cancer; correlation with imaging needed. False positives possible with benign conditions.
References: AUA Guidelines, 2023; Journal of Urology, Catalona WJ, 2022.
